Progesterone regulation of stem and progenitor cells in normal and malignant breast

Molecular and Cellular Endocrinology

Volumn 357, Issue 1-2, 2012, Pages 71-79

  Axlund, Sunshine Daddario ^a   Sartorius, Carol A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Hormone therapy; Mammary gland; Progenitor cells; Progesterone; Progesterone receptor; Stem cells

Indexed keywords

DOCETAXEL; ESTROGEN; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GESTAGEN; LETROZOLE; OSTEOCLAST DIFFERENTIATION FACTOR; PROGESTERONE; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER CELL; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CELL POPULATION; CELL TRANSFORMATION; CYTOPLASM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; HORMONAL THERAPY; HUMAN; MAMMARY GLAND; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; STEM CELL; TREATMENT RESPONSE;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; MICE; PROGESTERONE; PROGESTINS; RECEPTORS, PROGESTERONE; STEM CELLS;

EID: 84860331033     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.09.021     Document Type: Review

References (89)

1. Abd El-Rehim D.M., Pinder S.E., Paish C.E., Bell J., Blamey R.W., Robertson J.F., Nicholson R.I., Ellis I.O. Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol. 2004, 203:661-671.
2. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
3. Asselin-Labat M.L., Shackleton M., Stingl J., Vaillant F., Forrest N.C., Eaves C.J., Visvader J.E., Lindeman G.J. Steroid hormone receptor status of mouse mammary stem cells. J. Natl. Cancer Inst. 2006, 98:1011-1014.
4. Asselin-Labat M.L., Vaillant F., Sheridan J.M., Pal B., Wu D., Simpson E.R., Yasuda H., Smyth G.K., Martin T.J., Lindeman G.J., Visvader J.E. Control of mammary stem cell function by steroid hormone signalling. Nature 2010, 465:798-802.
5. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896, 2:104-107.
6. Beleut M., Rajaram R.D., Caikovski M., Ayyanan A., Germano D., Choi Y., Schneider P., Brisken C. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc. Natl. Acad. Sci. USA 2010, 107:2989-2994.
7. Beral V., Reeves G., Bull D., Green J. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J. Natl. Cancer Inst. 2011, 103:296-305.
8. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J. Mammary Gland Biol. Neoplasia 2002, 7:3-15.
9. Boecker W., Moll R., Poremba C., Holland R., Van Diest P.J., Dervan P., Burger H., Wai D., Ina Diallo R., Brandt B., Herbst H., Schmidt A., Lerch M.M., Buchwallow I.B. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab. Invest. 2002, 82:737-746.
10. Boecker W., Buerger H. Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. Cell Prolif. 2003, 36(Suppl. 1):73-84.
11. Boyd S. On oophorectomy in cancer of the breast. BMJ 1900, 2:1161-1167.
12. Brisken C., Park S., Vass T., Lydon J.P., O'Malley B.W., Weinberg R.A. A paracrine role for the epithelial progesterone receptor in mammary gland development. Proc. Natl. Acad. Sci. USA 1998, 95:5076-5081.
13. Brisken C., Heineman A., Chavarria T., Elenbaas B., Tan J., Dey S.K., McMahon J.A., McMahon A.P., Weinberg R.A. Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev. 2000, 14:650-654.
14. Chaffer C.L., Brueckmann I., Scheel C., Kaestli A.J., Wiggins P.A., Rodrigues L.O., Brooks M., Reinhardt F., Su Y., Polyak K., Arendt L.M., Kuperwasser C., Bierie B., Weinberg R.A. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. USA 2011, 108:7950-7955.
15. Cheang M.C., Voduc D., Bajdik C., Leung S., McKinney S., Chia S.K., Perou C.M., Nielsen T.O. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 2008, 14:1368-1376.
16. Chlebowski R.T., Anderson G.L., Gass M., Lane D.S., Aragaki A.K., Kuller L.H., Manson J.E., Stefanick M.L., Ockene J., Sarto G.E., Johnson K.C., Wactawski-Wende J., Ravdin P.M., Schenken R., Hendrix S.L., Rajkovic A., Rohan T.E., Yasmeen S., Prentice R.L. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010, 304:1684-1692.
17. Clarke R.B., Howell A., Potten C.S., Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 1997, 57:4987-4991.
18. Clarke R.B. Human breast cell proliferation and its relationship to steroid receptor expression. Climacteric 2004, 7:129-137.
19. Clarke R.B. Isolation and characterization of human mammary stem cells. Cell Prolif. 2005, 38:375-386.
20. Collaborative Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative group on hormonal factors in breast cancer. Lancet 1996, 347:1713-1727.
21. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., Rimm D.L., Wong H., Rodriguez A., Herschkowitz J.I., Fan C., Zhang X., He X., Pavlick A., Gutierrez M.C., Renshaw L., Larionov A.A., Faratian D., Hilsenbeck S.G., Perou C.M., Lewis M.T., Rosen J.M., Chang J.C. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. USA 2009, 106:13820-13825.
22. Delgado R.C., Lubian Lopez D.M. Prognosis of breast cancers detected in women receiving hormone replacement therapy. Maturitas 2001, 38:147-156.
23. Dontu G., Abdallah W.M., Foley J.M., Jackson K.W., Clarke M.F., Kawamura M.J., Wicha M.S. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17:1253-1270.
24. Dontu G., Jackson K.W., McNicholas E., Kawamura M.J., Abdallah W.M., Wicha M.S. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004, 6:R605-R615.
25. Faivre E.J., Lange C.A. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol. Cell. Biol. 2007, 27:466-480.
26. Farnie G., Clarke R.B. Mammary stem cells and breast cancer - role of Notch signalling. Stem Cell Rev. 2007, 3:169-175.
27. Fernandez-Valdivia R., Mukherjee A., Ying Y., Li J., Paquet M., DeMayo F.J., Lydon J.P. The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev. Biol. 2009, 328:127-139.
28. Fernandez-Valdivia R., Jeong J., Mukherjee A., Soyal S.M., Li J., Ying Y., Demayo F.J., Lydon J.P. A mouse model to dissect progesterone signaling in the female reproductive tract and mammary gland. Genesis 2010, 48:106-113.
29. Fournier A., Fabre A., Mesrine S., Boutron-Ruault M.C., Berrino F., Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J. Clin. Oncol. 2008, 26:1260-1268.
30. Gajdos C., Tartter P.I., Babinszki A. Breast cancer diagnosed during hormone replacement therapy. Obstet. Gynecol. 2000, 95:513-518.
31. Ghatge R.P., Jacobsen B.M., Schittone S.A., Horwitz K.B. The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. Breast Cancer Res. 2005, 7:R1036-R1050.
32. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S., Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
33. Giulianelli S., Herschkowitz J.I., Patel V., Lamb C.A., Gutkind J.S., Molinolo A., Perou C.M., Lanari C. MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements. Breast Cancer Res. Treat. 2011, 129:49-67.
34. Gonzalez-Suarez E., Jacob A.P., Jones J., Miller R., Roudier-Meyer M.P., Erwert R., Pinkas J., Branstetter D., Dougall W.C. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107.
35. Graham J.D., Yager M.L., Hill H.D., Byth K., O'Neill G.M., Clarke C.L. Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Mol. Endocrinol. 2005, 19:2713-2735.
36. Graham J.D., Mote P.A., Salagame U., van Dijk J.H., Balleine R.L., Huschtscha L.I., Reddel R.R., Clarke C.L. DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 2009, 150:3318-3326.
37. Graham J.D., Mote P.A., Salagame U., Balleine R.L., Huschtscha L.I., Clarke C.L. Hormone-responsive model of primary human breast epithelium. J. Mammary Gland Biol. Neoplasia 2009, 14:367-379.
38. Grimm S.L., Bu W., Longley M.A., Roop D.R., Li Y., Rosen J.M. Keratin 6 is not essential for mammary gland development. Breast Cancer Res. 2006, 8:R29.
39. Gusterson B. Do 'basal-like' breast cancers really exist?. Nat. Rev .Cancer 2009, 9:128-134.
40. Gusterson B.A., Ross D.T., Heath V.J., Stein T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 2005, 7:143-148.
41. Hankinson S.E., Colditz G.A., Willett W.C. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res. 2004, 6:213-218.
42. Hargreaves D.F., Knox F., Swindell R., Potten C.S., Bundred N.J. Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy. Br. J. Cancer 1998, 78:945-949.
43. Harrison H., Farnie G., Howell S.J., Rock R.E., Stylianou S., Brennan K.R., Bundred N.J., Clarke R.B. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010, 70:709-718.
44. Horwitz K.B., Dye W.W., Harrell J.C., Kabos P., Sartorius C.A. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc. Natl. Acad. Sci. USA 2008, 105:5774-5779.
45. Horwitz K.B., Sartorius C.A. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J. Clin. Endocrinol. Metab. 2008, 93:3295-3298.
46. Huggins C., Moon R.C., Morii S. Extinction of experimental mammary cancer. I. Estradiol-17beta and progesterone. Proc. Natl. Acad. Sci. USA 1962, 48:379-386.
47. Iliopoulos D., Hirsch H.A., Wang G., Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. USA 2011, 108:1397-1402.
48. Jacobsen B.M., Richer J.K., Schittone S.A., Horwitz K.B. New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J. Biol. Chem. 2002, 277:27793-27800.
49. Jacobsen B.M., Schittone S.A., Richer J.K., Horwitz K.B. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol. Endocrinol. 2005, 19:574-587.
50. Jones D.H., Nakashima T., Sanchez O.H., Kozieradzki I., Komarova S.V., Sarosi I., Morony S., Rubin E., Sarao R., Hojilla C.V., Komnenovic V., Kong Y.Y., Schreiber M., Dixon S.J., Sims S.M., Khokha R., Wada T., Penninger J.M. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692-696.
51. Joshi P.A., Jackson H.W., Beristain A.G., Di Grappa M.A., Mote P.A., Clarke C.L., Stingl J., Waterhouse P.D., Khokha R. Progesterone induces adult mammary stem cell expansion. Nature 2010, 465:803-807.
52. Kabos P., Haughian J.M., Wang X., Dye W.W., Finlayson C., Elias A., Horwitz K.B., Sartorius C.A. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res. Treat. 2011, 128:45-55.
53. Kariagina A., Xie J., Leipprandt J.R., Haslam S.Z. Amphiregulin mediates estrogen, progesterone, and egfr signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers. Horm. Cancer 2010, 1:229-244.
54. Kariagina, A., Kramer, A.N., Miller, K.N. Haslam, S.Z., 2010b. Progesterone alters tumor cell composition, increases tumor cell proliferation and survival, and promotes invasive behavior in carcinogen-induced mammary cancer in the rat. In: The 92nd Annual Meeting of the Endocrine Society, San Diego, CA. OR12-2.
55. Katiyar P., Ma Y., Fan S., Pestell R.G., Furth P.A., Rosen E.M. Regulation of progesterone receptor signaling by BRCA1 in mammary cancer. Nucl. Recept. Signal 2006, 4:e006.
56. Kobayashi S., Stice J.P., Kazmin D., Wittmann B.M., Kimbrel E.A., Edwards D.P., Chang C.Y., McDonnell D.P. Mechanisms of progesterone receptor inhibition of inflammatory responses in cellular models of breast cancer. Mol. Endocrinol. 2010, 24:2292-2302.
57. Kordon E., Lanari C., Meiss R., Elizalde P., Charreau E., Dosne Pasqualini C. Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate. Breast Cancer Res. Treat. 1990, 17:33-43.
58. Lanari C., Molinolo A.A., Pasqualini C.D. Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c female mice. Cancer Lett. 1986, 33:215-223.
59. Lanari C., Lamb C.A., Fabris V.T., Helguero L.A., Soldati R., Bottino M.C., Giulianelli S., Cerliani J.P., Wargon V., Molinolo A. The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr. Relat. Cancer 2009, 16:333-350.
60. Leo J.C., Wang S.M., Guo C.H., Aw S.E., Zhao Y., Li J.M., Hui K.M., Lin V.C. Gene regulation profile reveals consistent anticancer properties of progesterone in hormone-independent breast cancer cells transfected with progesterone receptor. Int. J. Cancer 2005, 117:561-568.
61. Leong K.G., Niessen K., Kulic I., Raouf A., Eaves C., Pollet I., Karsan A. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J. Exp. Med. 2007, 204:2935-2948.
62. Lim E., Vaillant F., Wu D., Forrest N.C., Pal B., Hart A.H., Asselin-Labat M.L., Gyorki D.E., Ward T., Partanen A., Feleppa F., Huschtscha L.I., Thorne H.J., Fox S.B., Yan M., French J.D., Brown M.A., Smyth G.K., Visvader J.E., Lindeman G.J. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 2009, 15:907-913.
63. Lindvall C., Bu W., Williams B.O., Li Y. Wnt signaling, stem cells, and the cellular origin of breast cancer. Stem Cell Rev. 2007, 3:157-168.
64. Lydon J.P., Ge G., Kittrell F.S., Medina D., O'Malley B.W. Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function. Cancer Res. 1999, 59:4276-4284.
65. Ma Y., Katiyar P., Jones L.P., Fan S., Zhang Y., Furth P.A., Rosen E.M. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol. Endocrinol. 2006, 20:14-34.
66. Medina D., Sivaraman L., Hilsenbeck S.G., Conneely O., Ginger M., Rosen J., Omalle B.W. Mechanisms of hormonal prevention of breast cancer. Ann. NY Acad. Sci. 2001, 952:23-35.
67. Medina D. Breast cancer: the protective effect of pregnancy. Clin. Cancer Res. 2004, 10:380S-384S.
68. Molyneux G., Geyer F.C., Magnay F.A., McCarthy A., Kendrick H., Natrajan R., Mackay A., Grigoriadis A., Tutt A., Ashworth A., Reis-Filho J.S., Smalley M.J. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010, 7:403-417.
69. Mulac-Jericevic B., Lydon J.P., DeMayo F.J., Conneely O.M. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc. Natl. Acad. Sci. USA 2003, 100:9744-9749.
70. Musgrove E.A., Lee C.S., Sutherland R.L. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol. Cell Biol. 1991, 11:5032-5043.
71. Narod S.A. Hormonal prevention of hereditary breast cancer. Ann. NY Acad. Sci. 2001, 952:36-43.
72. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
73. Pike M.C., Spicer D.V., Dahmoush L., Press M.F. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 1993, 15:17-35.
74. Proia T.A., Keller P.J., Gupta P.B., Klebba I., Jones A.D., Sedic M., Gilmore H., Tung N., Naber S.P., Schnitt S., Lander E.S., Kuperwasser C. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 2011, 8:149-163.
75. Richer J.K., Jacobsen B.M., Manning N.G., Abel M.G., Wolf D.M., Horwitz K.B. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J. Biol. Chem. 2002, 277:5209-5218.
76. Roarty K., Rosen J.M. Wnt and mammary stem cells: hormones cannot fly wingless. Curr. Opin. Pharmacol. 2010, 10:643-649.
77. Russo J., Ao X., Grill C., Russo I.H. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res. Treat. 1999, 53:217-227.
78. Santos S.J., Aupperlee M.D., Xie J., Durairaj S., Miksicek R., Conrad S.E., Leipprandt J.R., Tan Y.S., Schwartz R.C., Haslam S.Z. Progesterone receptor A-regulated gene expression in mammary organoid cultures. J. Steroid Biochem. Mol. Biol. 2009, 115:161-172.
79. Sartorius C.A., Harvell D.M., Shen T., Horwitz K.B. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. Cancer Res. 2005, 65:9779-9788.
80. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat. Rev. Cancer 2006, 6:281-291.
81. Schramek D., Leibbrandt A., Sigl V., Kenner L., Pospisilik J.A., Lee H.J., Hanada R., Joshi P.A., Aliprantis A., Glimcher L., Pasparakis M., Khokha R., Ormandy C.J., Widschwendter M., Schett G., Penninger J.M. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102.
82. Shackleton M., Vaillant F., Simpson K.J., Stingl J., Smyth G.K., Asselin-Labat M.L., Wu L., Lindeman G.J., Visvader J.E. Generation of a functional mammary gland from a single stem cell. Nature 2006, 439:84-88.
83. Shen T., Horwitz K.B., Lange C.A. Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol. Cell Biol. 2001, 21:6122-6131.
84. Shyamala G., Yang X., Cardiff R.D., Dale E. Impact of progesterone receptor on cell-fate decisions during mammary gland development. Proc. Natl. Acad. Sci. USA 2000, 97:3044-3049.
85. Sleeman K.E., Kendrick H., Robertson D., Isacke C.M., Ashworth A., Smalley M.J. Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J. Cell Biol. 2007, 176:19-26.
86. Stingl J., Eirew P., Ricketson I., Shackleton M., Vaillant F., Choi D., Li H.I., Eaves C.J. Purification and unique properties of mammary epithelial stem cells. Nature 2006, 439:993-997.
87. van de Rijn M., Perou C.M., Tibshirani R., Haas P., Kallioniemi O., Kononen J., Torhorst J., Sauter G., Zuber M., Kochli O.R., Mross F., Dieterich H., Seitz R., Ross D., Botstein D., Brown P. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol. 2002, 161:1991-1996.
88. Villadsen R., Fridriksdottir A.J., Ronnov-Jessen L., Gudjonsson T., Rank F., LaBarge M.A., Bissell M.J., Petersen O.W. Evidence for a stem cell hierarchy in the adult human breast. J. Cell Biol. 2007, 177:87-101.
89. Zeps N., Bentel J.M., Papadimitriou J.M., D'Antuono M.F., Dawkins H.J. Estrogen receptor-negative epithelial cells in mouse mammary gland development and growth. Differentiation 1998, 62:221-226.